Bradykinin-induced lung inflammation and bronchoconstriction: role in parainfluenze-3 virus-induced inflammation and airway hyperreactivity.
Inhaled bradykinin causes bronchoconstriction in asthmatic subjects but not nonasthmatics. To date, animal studies with inhaled bradykinin have been performed only in anesthetized guinea pigs and rats, where it causes bronchoconstriction through sensory nerve pathways. In the present study, airway function was recorded in conscious guinea pigs by whole-body plethysmography. Inhaled bradykinin (1 mM, 20 s) caused bronchoconstriction and influx of inflammatory cells to the lungs, but only when the enzymatic breakdown of bradykinin by angiotensin-converting enzyme and neutral endopeptidase was inhibited by captopril (1 mg/kg i.p.) and phosphoramidon (10 mM, 20-min inhalation), respectively. The bronchoconstriction and cell influx were antagonized by the B(2) kinin receptor antagonist 4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl}piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132) when given by inhalation (1 and 10 μM, 20 min) and are therefore mediated via B(2) kinin receptors. However, neither intraperitioneal MEN16132 nor the peptide B(2) antagonist icatibant, by inhalation, antagonized these bradykinin responses. Sensitization of guinea pigs with ovalbumin was not sufficient to induce airway hyperreactivity (AHR) to the bronchoconstriction by inhaled bradykinin. However, ovalbumin challenge of sensitized guinea pigs caused AHR to bradykinin and histamine. Infection of guinea pigs by nasal instillation of parainfluenza-3 virus produced AHR to inhaled histamine and lung influx of inflammatory cells. These responses were attenuated by the bradykinin B(2) receptor antagonist MEN16132 and H-(4-chloro)DPhe-2'(1-naphthylalanine)-(3-aminopropyl)guanidine (VA999024), an inhibitor of tissue kallikrein, the enzyme responsible for lung synthesis of bradykinin. These results suggest that bradykinin is involved in virus-induced inflammatory cell influx and AHR.
Broadley
Kenneth J
KJ
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK. broadleykj@cardiff.ac.uk
Blair
Alan E
AE
Kidd
Emma J
EJ
Bugert
Joachim J
JJ
Ford
William R
WR
D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D065094:Bradykinin B2 Receptor Antagonists; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016084:Bronchoconstriction / Q000187:drug effects*; D002216:Captopril / Q000494:pharmacology; D002452:Cell Count; D006020:Glycopeptides / Q000494:pharmacology; D006168:Guinea Pigs; D006632:Histamine / Q000494:pharmacology; D008297:Male; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010047:Ovalbumin / Q000276:immunology; D010224:Parainfluenza Virus 3, Human; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D010993:Plethysmography, Whole Body; D011014:Pneumonia / Q000139:chemically induced* / Q000473:pathology; D011480:Protease Inhibitors / Q000494:pharmacology; D010253:Respirovirus Infections / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D020840:Tissue Kallikreins / Q000037:antagonists & inhibitors
C506838:(4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2H-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium; D065094:Bradykinin B2 Receptor Antagonists; C440019:FE 999024; D006020:Glycopeptides; D010455:Peptides; D011480:Protease Inhibitors; D013449:Sulfonamides; D006632:Histamine; D010047:Ovalbumin; D002216:Captopril; D009952:Ornithine; D020840:Tissue Kallikreins; D001920:Bradykinin; C008890:phosphoramidon